<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>During <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, neurons are injured by various mechanisms including excitotoxicity, <z:mp ids='MP_0003674'>oxidative stress</z:mp>, and <z:mp ids='MP_0001845'>inflammatory responses</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, pharmacological manipulation of multiple cytotoxic pathways has been pursued for the treatment of ischemic injury </plain></SENT>
<SENT sid="2" pm="."><plain>Cis-<z:chebi fb="0" ids="435764">hinokiresinol</z:chebi>, a naturally occurring <z:chebi fb="0" ids="26004">phenylpropanoid</z:chebi>, was previously reported to possess anti-oxidant, anti-inflammatory and <z:chebi fb="0" ids="50114">estrogen</z:chebi>-like activities </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study, we investigated anti-ischemic effects of trans- and cis-<z:chebi fb="0" ids="435764">hinokiresinols</z:chebi> using in vitro as well as in vivo experimental models </plain></SENT>
<SENT sid="4" pm="."><plain>The ORAC and DPPH assays showed that two isomers had similar free radical scavenging activities </plain></SENT>
<SENT sid="5" pm="."><plain>However, only trans-<z:chebi fb="0" ids="435764">hinokiresinol</z:chebi> significantly decreased neuronal injury in cultured cortical neurons exposed to oxygen-<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation (75 min) followed by re-oxygenation (9 h) </plain></SENT>
<SENT sid="6" pm="."><plain>The differential neuroprotective effect could be due to the stereo-specific augmentation of Cu/Zn-SOD activity by trans-<z:chebi fb="0" ids="435764">hinokiresinol</z:chebi>, when compared with cis-<z:chebi fb="0" ids="435764">hinokiresinol</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Similarly, in rats subjected to transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (1.5 h) followed by 24-h reperfusion, pre-ischemic treatment with trans-<z:chebi fb="0" ids="435764">hinokiresinol</z:chebi>, but not with cis-isomer, reduced cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="8" pm="."><plain>Interestingly, however, post-ischemic treatment with both <z:chebi fb="0" ids="435764">hinokiresinols</z:chebi> (2 and 7 h after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>) significantly reduced cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>When administered after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, trans-<z:chebi fb="0" ids="435764">hinokiresinol</z:chebi>, but not its cis-isomer reduced nitrotyrosine immunoreactivity in ischemic regions </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast, both <z:chebi fb="0" ids="435764">hinokiresinols</z:chebi> suppressed neutrophil infiltration and IL-1β release to a similar extent </plain></SENT>
<SENT sid="11" pm="."><plain>The observed differential anti-oxidant, but comparable anti-inflammatory, activities may explain the stereo-specific anti-ischemic activities and different therapeutic time windows of the <z:chebi fb="0" ids="435764">hinokiresinols</z:chebi> examined </plain></SENT>
<SENT sid="12" pm="."><plain>More detailed delineation of the anti-ischemic mechanism(s) of <z:chebi fb="0" ids="435764">hinokiresinols</z:chebi> may provide a better strategy for development of efficacious regimens for cerebral <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
</text></document>